UCB Pharma Oy Finland - search results

European Union - English - EMA (European Medicines Agency)

lacosamide ucb

ucb pharma s.a. - lacosamide - epilepsies, partial - antiepileptics, - lacosamide ucb is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.,

European Union - English - EMA (European Medicines Agency)

bimzelx

ucb pharma s.a. - bimekizumab - psoriasis - immunosuppressants - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards).axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids).ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.

European Union - English - EMA (European Medicines Agency)

evenity

ucb pharma s.a. - romosozumab - osteoporosis - drugs for treatment of bone diseases - evenity is indicated in treatment of severe osteoporosis in postmenopausal women at high risk of fracture.